CancerCancel vs Targeted Asthma Therapy

CancerCancel provides a simple AR game to familiarised you with different risk factors for different types of cancer. It'll be things you may come across with in your everyday life that have the risk to harm you, so you shouldn't overindulge. With CancerCancel, you can know the general location of cancer in your anatomy, what may cause it, and how to prevent it. - Learn about how cancer is formed in the first place with our floating cell. - Visualise your organs and the types of cancer that can formed in it. - Learn what's good and bad for your body through our game.

Asthma is a complex and heterogeneous chronic disease that manifests differently across patient populations, influenced by factors such as age, ethnicity, and comorbid conditions. This program explores the underlying role of type 2 inflammation in asthma pathophysiology and highlights how biomarkers—including eosinophil counts, fractional exhaled nitric oxide (FeNO), and IgE levels—can inform a more personalized approach to treatment. Participants will examine emerging evidence supporting the use of biomarker testing to define asthma phenotypes and optimize therapeutic strategies. Building on the latest Global Initiative for Asthma (GINA 2025) recommendations, this provides guidance on assessing disease severity, evaluating comorbidities, and identifying patients most likely to benefit from biologic therapy. Clinical data and practical decision-making frameworks will be reviewed that compare anti-IgE, anti–IL-5/5R, anti–IL-4/13, and anti–TSLP biologics, emphasizing their safety, efficacy, and demonstrated benefits in reducing exacerbations and improving lung function.